1/3/2014 11:17:56 AM
Jazz Pharmaceuticals Plc (JAZZ) just got more alluring as a takeover target after adding to its suite of medicines for rare diseases.
With drugmakers on the prowl for targets in Ireland because of the country’s lower corporate tax rate, investors have been speculating that Dublin-based Jazz may be among the next companies to draw bids. Jazz’s enviable tax base is only part of the appeal as the $7.3 billion company bolsters its product lineup with the $1 billion purchase of rare-disease drug developer Gentium SpA. (GENT)
Help employers find you! Check out all the jobs and post your resume.
comments powered by